Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

6.85

Margin Of Safety %

Put/Call OI Ratio

0.69

EPS Next Q Diff

0.22

EPS Last/This Y

-1.36

EPS This/Next Y

0.29

Price

65.56

Target Price

91.25

Analyst Recom

1

Performance Q

44.25

Relative Volume

0.58

Beta

1.09

Ticker: MRUS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-07MRUS52.580.630.0116649
2025-07-08MRUS52.330.630.1216712
2025-07-09MRUS54.450.630.0516693
2025-07-10MRUS55.10.630.0816795
2025-07-11MRUS54.470.620.0016845
2025-07-14MRUS55.620.620.0016836
2025-07-15MRUS54.670.615.2017055
2025-07-16MRUS56.50.610.0017094
2025-07-17MRUS61.490.610.2017098
2025-07-18MRUS63.310.620.2317100
2025-07-21MRUS62.390.490.0712116
2025-07-22MRUS63.320.490.2512131
2025-07-23MRUS64.150.490.2712139
2025-07-24MRUS65.690.496.8512153
2025-07-25MRUS66.940.625.4113182
2025-07-28MRUS65.660.680.3813716
2025-07-29MRUS65.840.681.1813724
2025-07-30MRUS66.270.682.5713770
2025-07-31MRUS66.240.690.7913792
2025-08-01MRUS65.50.693.8613843
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-07MRUS52.60-42.0-51.6-4.71
2025-07-08MRUS52.33-42.0-58.8-4.71
2025-07-09MRUS54.51-42.0-77.9-4.71
2025-07-10MRUS55.11-42.0-65.3-4.71
2025-07-11MRUS54.50-42.0-60.8-4.71
2025-07-14MRUS55.62-42.0-69.1-4.71
2025-07-15MRUS54.99-42.0-56.2-4.71
2025-07-16MRUS56.48-42.0-71.8-4.71
2025-07-17MRUS61.44-42.0-96.2-4.71
2025-07-18MRUS63.27-42.0-72.7-4.71
2025-07-21MRUS62.37-42.0-55.2-4.71
2025-07-22MRUS63.31-42.0-66.9-4.71
2025-07-23MRUS64.15-42.0-66.5-4.71
2025-07-24MRUS65.69-42.5-70.4-4.71
2025-07-25MRUS66.82-42.5-67.7-4.71
2025-07-28MRUS65.93-42.5-55.5-4.71
2025-07-29MRUS65.92-42.5-62.8-4.71
2025-07-30MRUS66.16-42.5-62.7-4.71
2025-07-31MRUS66.24-42.5-61.3-4.71
2025-08-01MRUS65.56-42.5-56.8-4.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-07MRUS-0.46-1.507.54
2025-07-08MRUS-0.46-1.507.54
2025-07-09MRUS-0.46-1.507.54
2025-07-10MRUS-0.46-1.507.54
2025-07-11MRUS-0.75-1.507.75
2025-07-14MRUS-0.75-1.477.75
2025-07-15MRUS-0.75-1.477.75
2025-07-16MRUS-0.75-1.477.75
2025-07-17MRUS-0.75-1.477.75
2025-07-18MRUS-1.05-1.477.75
2025-07-21MRUS-1.05-1.487.75
2025-07-22MRUS-1.05-1.487.75
2025-07-23MRUS-1.05-1.487.75
2025-07-24MRUS-1.05-1.487.75
2025-07-25MRUS-1.05-1.486.85
2025-07-28MRUS-1.05-1.516.85
2025-07-29MRUS-1.05-1.516.85
2025-07-30MRUS-1.05-1.516.85
2025-07-31MRUS-1.05-1.516.85
2025-08-01MRUS-1.05-1.516.85
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.4

Avg. EPS Est. Current Quarter

-1.15

Avg. EPS Est. Next Quarter

-1.18

Insider Transactions

-1.05

Institutional Transactions

-1.51

Beta

1.09

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

20

Growth Score

34

Sentiment Score

90

Actual DrawDown %

3

Max Drawdown 5-Year %

-60.4

Target Price

91.25

P/E

Forward P/E

PEG

P/S

89.21

P/B

7.61

P/Free Cash Flow

EPS

-4.12

Average EPS Est. Cur. Y​

-4.71

EPS Next Y. (Est.)

-4.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-506.73

Relative Volume

0.58

Return on Equity vs Sector %

-70.3

Return on Equity vs Industry %

-51.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

-56.8
Merus N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 260
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
stock quote shares MRUS – Merus N.V Stock Price stock today
news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch MRUS – Merus N.V yahoo finance google finance
stock history MRUS – Merus N.V invest stock market
stock prices MRUS premarket after hours
ticker MRUS fair value insiders trading